State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary
about
A genome-wide association study of carotid atherosclerosis in HIV-infected menIncreased cardiovascular disease risk in the HIV-positive population on ART: potential role of HIV-Nef and TatManaging dyslipidemia in HIV/AIDS patients: challenges and solutionsCardiovascular Complications of HIV-Associated Immune DysfunctionInflammation, coagulation and cardiovascular disease in HIV-infected individualsAngiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trialUse Your Words Carefully: What Is a Chronic Disease?Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study).Cardiovascular disease risk among Chinese antiretroviral-naïve adults with advanced HIV disease.Association between kidney function and albuminuria with cardiovascular events in HIV-infected personsBlood pressure level impacts risk of death among HIV seropositive adults in Kenya: a retrospective analysis of electronic health records.The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms.Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infectionYoga lifestyle intervention reduces blood pressure in HIV-infected adults with cardiovascular disease risk factors.Clinical research directions in pediatric cardiology.Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV diseaseBiomarkers of vascular dysfunction in children infected with human immunodeficiency virus-1.HIV infection, inflammation, immunosenescence, and aging.Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection.Monocyte activation from interferon-α in HIV infection increases acetylated LDL uptake and ROS productionBiomarkers and HIV-associated cardiovascular disease.Lipodystrophy defined by Fat Mass Ratio in HIV-infected patients is associated with a high prevalence of glucose disturbances and insulin resistance.Immunologic basis of cardiovascular disease in HIV-infected adults.Quantitative proteomics for cardiac biomarker discovery using isoproterenol-treated nonhuman primates.Relationship between neck circumference and cardiometabolic parameters in HIV-infected and non-HIV-infected adultsCardio-metabolic effectsof HIV protease inhibitors (lopinavir/ritonavir)Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular diseaseHIV and general cardiovascular risk.Reduced IgM levels and elevated IgG levels against oxidized low-density lipoproteins in HIV-1 infection.Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialPreclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study.Epidemiology and management of antiretroviral-associated cardiovascular disease.Lymphoid fibrosis occurs in long-term nonprogressors and persists with antiretroviral therapy but may be reversible with curative interventions.Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy.Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children.Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population.Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patientsExploratory study: evaluating the effects of fish oil and controlled diet to reduce triglyceride levels in HIV.Physical fitness in children infected with the human immunodeficiency virus: associations with highly active antiretroviral therapyAssessment of biomarkers of cardiovascular risk among HIV type 1-infected adolescents: role of soluble vascular cell adhesion molecule as an early indicator of endothelial inflammation.
P2860
Q24622468-1C6358E7-9736-4A6B-BF21-13A0B4392D91Q28080948-DF9D3C03-5CA5-42F1-A4E8-E89C5E48D3B3Q28084941-18BD5A5C-9915-42C7-9B75-281CBF64B8B0Q28084981-3D91843A-F4DD-48C6-8B87-6815F322E4ACQ28483645-917895FF-495B-4B48-B1FC-E2827E086EA3Q28484460-B9D56AB0-01BE-48E2-89A9-6B6E562B4A9AQ28595560-A42CC11B-4069-4D5C-B6EC-64046ADD55A9Q33404972-C09CFEBC-FCE5-4448-930F-E71B6E0C1100Q33582629-343262A2-134A-4685-94CF-15F1CFF0135DQ33692733-49733DED-AE74-4233-BDE6-3503DC4484D9Q33712941-219080DB-4445-4A94-90D5-DA70CEBE18B6Q33889580-E7CF2FDF-21E0-477B-9630-A0652755BB3AQ33907642-E572912E-758D-4D83-815C-73852B5F9A64Q33926811-EC14CAB6-E27A-4FE2-8113-D833826FADE0Q33944043-881E1603-F68E-4554-9664-D84EC0353D0AQ34077477-5832C937-D2C8-4435-8504-65F6DB9A618BQ34147987-31C9865B-F871-4C06-AAFC-768ECF453B70Q34150710-0F3F56E4-EA7A-4F21-A3A4-F02ACC7FFF28Q34156361-6C38E79F-929C-404F-8C9A-D7E2EAB65C96Q34292033-18330A6A-17A7-4AE9-8216-3E991C54568FQ34335486-7D9AC743-3251-4DC7-B805-778EE7A93557Q34367498-EB17EB85-126C-4743-8C14-E0932DAFB6BAQ34638205-0D3574E3-1CDD-4433-9DEC-EC7DFF942F57Q34669434-DA8DC450-CF9D-4714-A6E0-BA992FB8523EQ34718269-4AE5F476-6D61-46A5-B566-113299171DA6Q35009815-59A06336-8DB6-4504-B604-66B6A2611AB4Q35104006-083DB6E2-103E-46AF-900E-AED77EE87F9AQ35118909-02B931FF-9FE4-429E-BC0C-420E3A636122Q35122438-5E243410-0E93-4EE3-A3A9-94B073F766AEQ35124939-E6DFCA77-334B-41AE-B9E8-8B8CD5CAF3AEQ35166149-59975FB5-14E7-45F8-9941-C411B2D05584Q35338096-26B3948A-71DA-46CE-87CB-CAEB7B78689CQ35558823-5B196204-BC62-438B-A405-5A9847862319Q35796695-5A8EC40E-A573-4738-8F39-9E501EA1641AQ35815450-F15ED084-0311-4AA8-A94C-2FE62C8C7B57Q35949949-0D23B67B-7CDA-4619-85D1-5C99C1D7DA1CQ36379615-5C3AAB27-D38A-40C0-87F9-79AAB3D274F8Q36460278-F4E0E992-74BD-440D-8647-257D221F0356Q36509694-72EEABAE-BC6C-499D-A7A3-73DE84C3F40CQ36634946-49B70183-2B27-405E-BF4C-DF848B620563
P2860
State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
State of the science conferenc ...... th HIV/AIDS: executive summary
@ast
State of the science conferenc ...... th HIV/AIDS: executive summary
@en
type
label
State of the science conferenc ...... th HIV/AIDS: executive summary
@ast
State of the science conferenc ...... th HIV/AIDS: executive summary
@en
prefLabel
State of the science conferenc ...... th HIV/AIDS: executive summary
@ast
State of the science conferenc ...... th HIV/AIDS: executive summary
@en
P2093
P2860
P50
P1433
P1476
State of the science conferenc ...... th HIV/AIDS: executive summary
@en
P2093
Carl Grunfeld
Colleen M Hadigan
Donald P Kotler
Judith S Currier
Kathleen Squires
Michael P Dubé
Morris Schambelan
Peter W F Wilson
Priscilla Y Hsue
Robert H Eckel
P2860
P304
P356
10.1161/CIRCULATIONAHA.107.189622
P407
P577
2008-06-19T00:00:00Z